Yosr Hicheri
Overview
Explore the profile of Yosr Hicheri including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
515
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bertoli S, Berard E, Peterlin P, Guieze R, Desbrosses Y, Hicheri Y, et al.
Haematologica
. 2025 Feb;
PMID: 39911128
Not available.
2.
Cullot G, Lagarde V, Cayuela J, Prouzet-Mauleon V, Turcq B, Hicheri Y, et al.
Ann Hematol
. 2025 Jan;
PMID: 39774950
Chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia patients largely benefit from an expanding tyrosine kinase inhibitors (TKIs) toolbox that has improved the outcome of both diseases. However, TKI...
3.
Berton G, Hospital M, Garciaz S, Rouzaud C, Maisano V, Hicheri Y, et al.
Eur J Haematol
. 2025 Jan;
114(4):679-689.
PMID: 39761963
Acute myeloid leukemias (AMLs) are the hematological malignancies with the highest need for intensive care unit (ICU) admission due to their association with various life-threatening situations. Limited data exist regarding...
4.
Roth A, Fu R, He G, Alzahrani H, Chou S, Hicheri Y, et al.
Eur J Haematol
. 2024 Nov;
114(2):373-382.
PMID: 39535306
Objectives: To evaluate the tolerability of crovalimab versus eculizumab in C5 inhibitor (C5i)-naive and -experienced patients with PNH from COMMODORE 2, 3 and 1 (NCT04434092, NCT04654468 and NCT04432584). Methods: Pooled...
5.
Chevallier P, Leguay T, Delord M, Salek C, Kim R, Huguet F, et al.
J Clin Oncol
. 2024 Oct;
42(36):4327-4341.
PMID: 39418626
Purpose: The use of inotuzumab ozogamicin (InO), a conjugated anti-CD22 monoclonal antibody, is becoming a promising frontline treatment for older patients with ALL. Patients And Methods: EWALL-INO is an open-label...
6.
Soua A, Gilhodes J, Iat A, Hicheri Y, Saillard C, Rouzaud C, et al.
Eur J Haematol
. 2024 Aug;
113(6):751-757.
PMID: 39129130
Introduction: Elderly acute myeloid leukemia (AML) patients with poor-risk cytogenetics have a poor outcome with intensive chemotherapy (IC). While Venetoclax (VEN) has changed the outcomes of elderly unfit patients treatment,...
7.
Kim R, Chalandon Y, Rousselot P, Cayuela J, Huguet F, Balsat M, et al.
J Clin Oncol
. 2024 Jul;
42(26):3140-3150.
PMID: 39028928
Purpose: quantification is widely regarded as the standard for monitoring measurable residual disease (MRD) in Philadelphia chromosome-positive (Ph+) ALL. However, recent evidence of multilineage involvement questions the significance of MRD....
8.
Berton G, Sedaki B, Collomb E, Benachour S, Loschi M, Mohty B, et al.
Leuk Res
. 2024 Apr;
141:107500.
PMID: 38636413
Mutations in spliceosome genes (SRSF2, SF3B1, U2AF1, ZRSR2) correlate with inferior outcomes in patients treated with intensive chemotherapy for Acute Myeloid Leukemia. However, their prognostic impact in patients treated with...
9.
Chalandon Y, Rousselot P, Chevret S, Cayuela J, Kim R, Huguet F, et al.
Blood
. 2024 Mar;
143(23):2363-2372.
PMID: 38452207
We previously demonstrated that a reduced-intensity chemotherapy schedule can safely replace hyper-CVAD (cyclophosphamide-vincristine-doxorubicin [Adriamycin]-dexamethasone) cycle 1 when combined with imatinib in adults with Philadelphia-positive acute lymphoblastic leukemia. In the present...
10.
Garciaz S, Berton G, Hospital M, Guille A, Adelaide J, Saillard C, et al.
Leuk Lymphoma
. 2024 Feb;
65(5):700-703.
PMID: 38329727
No abstract available.